search
Arrowhead Pharmaceuticals
Trends
- 1Arrowhead Pharmaceuticals Stock Nears Five-Year High on Phase 3 Win▼ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval
Arrowhead Pharmaceuticals shares are on track to reach their highest level in more than five years after positive Phase 3 trial results, with retail investors celebrating the biotech's momentum. The company is reportedly aiming for a broader FDA approval than initially expected, fueling optimism about the commercial potential of its drug pipeline and driving renewed interest in the stock.